Literature DB >> 11427551

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

T R Walsh1, A Bolmström, A Qwärnström, P Ho, M Wootton, R A Howe, A P MacGowan, D Diekema.   

Abstract

The sensitivity and specificity of seven methods (agar dilution, broth microdilution, Etest at 0.5 and 2.0 McFarland (McF) inocula, two agar screening methods, and population studies [PS]) were evaluated in a double-blind study involving 284 methicillin-resistant Staphylococcus aureus (MRSA) strains and 45 Staphylococcus strains with reduced susceptibilities to vancomycin (SRSV). The results were compared to the population analysis profile-area under the curve ratio method (PAP-AUC ratio compared to that of Mu3) as described by Wootton et al. The agar screening method using brain heart infusion agar (6 microg of vancomycin per ml) gave a sensitivity of 22% and a specificity of 97%. A similar method using Mueller-Hinton agar (5 microg of vancomycin per ml) gave a sensitivity of 20% and a specificity of 99%. The PS method detected 34 false positives (12%) and gave a sensitivity of 71% and a specificity of 88%. Etest using 0.5 and 2.0 McF inocula gave sensitivities and specificities of 82 and 93% and of 96 and 97%, respectively. The best Etest interpretative criteria for the 2.0 McF inoculum was > or =8 mg of vancomycin per liter and > or =8 microg teicoplanin per ml or > or =12 microg of teicoplanin per ml. The direct colony suspension inoculum for this method was found to be equally accurate in detecting (hetero-)glycopeptide-intermediate S. aureus compared to the overnight broth inoculum preparation method. Agar dilution and broth microdilution using the NCCLS breakpoint criteria for vancomycin gave sensitivities and specificities of 20 and 100% and of 11 and 100%, respectively. Using the Etest with a 2.0 McF inoculum, six different media were assessed against a selection of SRSV (n = 48) and MRSA (n = 12). Brain heart infusion agar yielded the highest sensitivity and specificity values: 88 and 88%, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427551      PMCID: PMC88167          DOI: 10.1128/JCM.39.7.2439-2444.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany.

Authors:  G Bierbaum; K Fuchs; W Lenz; C Szekat; H G Sahl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

2.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Heterogeneous resistance to vancomycin in Staphylococcus aureus.

Authors:  R A Howe; M Wootton; T R Walsh; P M Bennett; A P Macgowan
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

5.  Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

Authors:  R F Pfeltz; V K Singh; J L Schmidt; M A Batten; C S Baranyk; M J Nadakavukaren; R K Jayaswal; B J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus.

Authors:  B Berger-Bächi; A Strässle; F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

7.  Bacteremia caused by staphylococci with inducible vancomycin heteroresistance.

Authors:  S S Wong; P L Ho; P C Woo; K Y Yuen
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

8.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

9.  Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.

Authors:  S K Hubert; J M Mohammed; S K Fridkin; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 10.  The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus.

Authors:  G A Ayliffe
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

View more
  105 in total

1.  Detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  Mary Jane Ferraro; Jana M Swenson; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

3.  Emergence of a teicoplanin-resistant small colony variant of Staphylococcus epidermidis during vancomycin therapy.

Authors:  H Adler; A Widmer; R Frei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-06       Impact factor: 3.267

Review 4.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

6.  agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  C K Kang; Y K Kim; S-I Jung; W B Park; K-H Song; K-H Park; P G Choe; H-C Jang; S Lee; Y-S Kim; Y G Kwak; K T Kwon; S Kiem; C-J Kim; E S Kim; H B Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-21       Impact factor: 3.267

7.  In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Authors:  Bram M W Diederen; Inge van Duijn; Piet Willemse; Jan A J W Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

9.  In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Authors:  Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.